IDHIFA vs RYDAPT

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 22, 2026·How we rate

Possible drug interaction. IDHIFA and RYDAPT are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	IDHIFA	RYDAPT
Rating	72/100	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	ENASIDENIB MESYLATE	MIDOSTAURIN
Manufacturer	Bristol Myers Squibb	Novartis
Dosage forms	Tablet	Capsule
Drug class	Isocitrate Dehydrogenase 2 Inhibitor	—
Boxed warning	Boxed warning	None
Treats	Acute Myeloid Leukemia	Acute Myeloid Leukemia, Hematologic Neoplasms, Systemic Mastocytosis

idhifa rydapt

Rating

72/100

70/100

Pharmacy pays

—

Type

Active ingredient

ENASIDENIB MESYLATE

MIDOSTAURIN

Manufacturer

Bristol Myers Squibb

Novartis

Dosage forms

Tablet

Capsule

Drug class

Isocitrate Dehydrogenase 2 Inhibitor

—

Boxed warning

None

Treats

Acute Myeloid Leukemia

Acute Myeloid Leukemia, Hematologic Neoplasms, Systemic Mastocytosis

Frequently asked questions

Which is better-rated, Idhifa or Rydapt?

By our independent rating, Idhifa scores higher — 3.6 vs 3.5 out of 5 for Rydapt. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Idhifa and Rydapt?

Idhifa contains Enasidenib Mesylate, while Rydapt contains Midostaurin — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.